Cell Based Assays Disease International 
Drug Target Review
JULY 6, 2023
allowing researchers to use “certain alternatives to animal testing, including cell-based assays and computer models, to obtain an exemption from the FDA to investigate the safety and effectiveness of a drug.” Three-dimensional organoids have been a popular choice in testing drugs to treat cancer and disease.
Drug Target Review
OCTOBER 24, 2024
Janette Thomas leads a small biotech company (Five Alarm Bio) 1 on a mission to develop drugs targeting the chronic diseases associated with ageing. Her company’s focus includes dementia, muscle wasting, and chronic wounds – diseases that disproportionately affect the elderly. Reference 1 Five Alarm Bio. cited 2024 Oct 17].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
OCTOBER 15, 2020
ASLAN believes ASLAN003 has the potential to bethe most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide. In preclinical studies, ASLAN003 was shown to be efficacious in animal models of MS and other autoimmune diseases.
Agency IQ
APRIL 12, 2024
Cell-based assays , while more complex to develop and use, offer another option for characterizing product activity at a slightly higher level, allowing sponsors to measure the further downstream effects of products (e.g., morphological cell changes or alterations in protein production or expression).
Drug Target Review
MAY 3, 2024
This is especially true in domains such as protein structure, predictive binding kinetics, and even in larger systemic investigations like cell migration models or disease progression. Ultimately, multi-omics represents an opportunity to generate high-fidelity, richly informative datasets that are often internally orthogonal.
Expert insights. Personalized for you.
105 
Let's personalize your content